Do analysts recommend AMRN or CALT?

Amarin currently has a consensus price target of $12.00, indicating a potential downside of 18.70%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts clearly believe Amarin is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer AMRN or OLMA?

In the previous week, Amarin and Amarin both had 5 articles in the media. Amarin's average media sentiment score of 0.97 beat Olema Pharmaceuticals' score of 0.38 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AMRN or DBVT?

Amarin has higher revenue and earnings than DBV Technologies. Amarin is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.45 -$38.80M -$0.65 N/A DBV Technologies $5.64M 168.39 -$146.95M -$4.46 N/A

Is AMRN or DBVT more profitable?

Amarin has a net margin of -15.51% compared to DBV Technologies' net margin of -2,895.37%. Amarin's return on equity of -2.99% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% DBV Technologies -2,895.37% -129.88% -88.84%

Does the media prefer AMRN or DBVT?

In the previous week, Amarin and Amarin both had 5 articles in the media. Amarin's average media sentiment score of 0.97 beat DBV Technologies' score of 0.41 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, SDGR or AMRN?

Amarin has lower revenue, but higher earnings than Schrodinger. Amarin is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Schrodinger $255.87M 4.08 -$103.26M -$1.41 N/A Amarin $213.65M 1.45 -$38.80M -$0.65 N/A

Is SDGR or AMRN more profitable?

Amarin has a net margin of -15.51% compared to Schrodinger's net margin of -40.61%. Amarin's return on equity of -2.99% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Schrodinger -40.61% -30.85% -15.32% Amarin -15.51% -2.99% -2.07%

Which has higher valuation & earnings, AMRN or AVLN?

Avalyn Pharma has lower revenue, but higher earnings than Amarin. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.45 -$38.80M -$0.65 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Does the media prefer AMRN or AVLN?

In the previous week, Amarin had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Amarin and 3 mentions for Avalyn Pharma. Amarin's average media sentiment score of 0.97 beat Avalyn Pharma's score of -0.30 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Amarin (AMRN) Competitors

$14.76 -0.13 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$14.32 -0.44 (-2.98%)

As of 05:18 PM Eastern

Compare

AMRN vs. CALT, OLMA, DBVT, SDGR, and AVLN

Should you buy Amarin stock or one of its competitors? MarketBeat compares Amarin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amarin include Calliditas Therapeutics AB (publ) (CALT), Olema Pharmaceuticals (OLMA), DBV Technologies (DBVT), Schrodinger (SDGR), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does Amarin compare to Calliditas Therapeutics AB (publ)?

Amarin (NASDAQ:AMRN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Amarin currently has a consensus price target of $12.00, indicating a potential downside of 18.70%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts clearly believe Amarin is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Amarin has a net margin of -15.51% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Amarin's return on equity of -2.99% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

In the previous week, Amarin had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Amarin and 0 mentions for Calliditas Therapeutics AB (publ). Amarin's average media sentiment score of 0.97 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Overall Sentiment
Amarin	Positive
Calliditas Therapeutics AB (publ)	Neutral

Amarin has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Amarin is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.45	-$38.80M	-$0.65	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Amarin has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

22.3% of Amarin shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amarin beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks.

How does Amarin compare to Olema Pharmaceuticals?

Amarin (NASDAQ:AMRN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Olema Pharmaceuticals has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, Amarin and Amarin both had 5 articles in the media. Amarin's average media sentiment score of 0.97 beat Olema Pharmaceuticals' score of 0.38 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amarin currently has a consensus target price of $12.00, indicating a potential downside of 18.70%. Olema Pharmaceuticals has a consensus target price of $44.10, indicating a potential upside of 349.08%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Amarin has higher revenue and earnings than Olema Pharmaceuticals. Amarin is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.45	-$38.80M	-$0.65	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

22.3% of Amarin shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Olema Pharmaceuticals beats Amarin on 8 of the 14 factors compared between the two stocks.

How does Amarin compare to DBV Technologies?

Amarin (NASDAQ:AMRN) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Amarin has higher revenue and earnings than DBV Technologies. Amarin is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.45	-$38.80M	-$0.65	N/A
DBV Technologies	$5.64M	168.39	-$146.95M	-$4.46	N/A

In the previous week, Amarin and Amarin both had 5 articles in the media. Amarin's average media sentiment score of 0.97 beat DBV Technologies' score of 0.41 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amarin has a net margin of -15.51% compared to DBV Technologies' net margin of -2,895.37%. Amarin's return on equity of -2.99% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

22.3% of Amarin shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amarin has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market.

Amarin currently has a consensus price target of $12.00, indicating a potential downside of 18.70%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 202.37%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Amarin beats DBV Technologies on 9 of the 16 factors compared between the two stocks.

How does Amarin compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Schrodinger currently has a consensus target price of $20.25, suggesting a potential upside of 43.11%. Amarin has a consensus target price of $12.00, suggesting a potential downside of 18.70%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrodinger is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Amarin has lower revenue, but higher earnings than Schrodinger. Amarin is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.08	-$103.26M	-$1.41	N/A
Amarin	$213.65M	1.45	-$38.80M	-$0.65	N/A

In the previous week, Amarin had 4 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Amarin and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.87 beat Amarin's score of 0.97 indicating that Schrodinger is being referred to more favorably in the media.

Company	Overall Sentiment
Schrodinger	Very Positive
Amarin	Positive

Amarin has a net margin of -15.51% compared to Schrodinger's net margin of -40.61%. Amarin's return on equity of -2.99% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Amarin	-15.51%	-2.99%	-2.07%

Schrodinger has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Amarin has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Summary

Schrodinger beats Amarin on 10 of the 16 factors compared between the two stocks.

How does Amarin compare to Avalyn Pharma?

Amarin (NASDAQ:AMRN) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, Amarin had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Amarin and 3 mentions for Avalyn Pharma. Amarin's average media sentiment score of 0.97 beat Avalyn Pharma's score of -0.30 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avalyn Pharma has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Avalyn Pharma's return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has lower revenue, but higher earnings than Amarin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.45	-$38.80M	-$0.65	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

Amarin presently has a consensus price target of $12.00, suggesting a potential downside of 18.70%. Avalyn Pharma has a consensus price target of $59.00, suggesting a potential upside of 106.80%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Summary

Avalyn Pharma beats Amarin on 7 of the 12 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRN vs. The Competition

Export

Metric	Amarin	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$312.23M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-22.71	18.83	24.65	23.63
Price / Sales	1.45	290.84	500.87	105.21
Price / Cash	41.25	120.20	43.05	54.72
Price / Book	0.67	8.00	10.43	6.70
Net Income	-$38.80M	$23.89M	$3.56B	$337.26M
7 Day Performance	1.58%	-3.49%	-1.39%	-1.41%
1 Month Performance	-1.93%	1.03%	0.86%	1.15%
1 Year Performance	15.13%	34.39%	19.42%	22.61%

Amarin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRN Amarin	0.7735 of 5 stars	$14.76 -0.9%	$12.00 -18.7%	+20.8%	$312.23M	$213.65M	N/A	360
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
OLMA Olema Pharmaceuticals	2.4941 of 5 stars	$12.71 -3.6%	$44.10 +247.0%	+138.6%	$1.15B	N/A	N/A	70
DBVT DBV Technologies	3.334 of 5 stars	$18.80 -1.6%	$48.50 +158.0%	+84.7%	$1.13B	N/A	N/A	80	News Coverage Gap Down
SDGR Schrodinger	3.1403 of 5 stars	$15.80 +3.9%	$20.25 +28.2%	-43.0%	$1.12B	$255.87M	N/A	790	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRN) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amarin (AMRN) Competitors

AMRN vs. CALT, OLMA, DBVT, SDGR, and AVLN

How does Amarin compare to Calliditas Therapeutics AB (publ)?

Summary

How does Amarin compare to Olema Pharmaceuticals?

Summary

How does Amarin compare to DBV Technologies?

Summary

How does Amarin compare to Schrodinger?

Summary

How does Amarin compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amarin (AMRN) Competitors

AMRN vs. CALT, OLMA, DBVT, SDGR, and AVLN

How does Amarin compare to Calliditas Therapeutics AB (publ)?

Do analysts recommend AMRN or CALT?

Is AMRN or CALT more profitable?

Does the media refer more to AMRN or CALT?

Which has preferable earnings & valuation, AMRN or CALT?

Which has more risk and volatility, AMRN or CALT?

Do institutionals and insiders have more ownership in AMRN or CALT?

Summary

How does Amarin compare to Olema Pharmaceuticals?

Is AMRN or OLMA more profitable?

Does the media prefer AMRN or OLMA?

Do analysts prefer AMRN or OLMA?

Which has more volatility and risk, AMRN or OLMA?

Which has preferable valuation & earnings, AMRN or OLMA?

Do institutionals & insiders have more ownership in AMRN or OLMA?

Summary

How does Amarin compare to DBV Technologies?

Which has preferable earnings and valuation, AMRN or DBVT?

Does the media prefer AMRN or DBVT?

Is AMRN or DBVT more profitable?

Do institutionals & insiders believe in AMRN or DBVT?

Which has more volatility and risk, AMRN or DBVT?

Do analysts rate AMRN or DBVT?

Summary

How does Amarin compare to Schrodinger?

Do institutionals & insiders hold more shares of SDGR or AMRN?

Do analysts rate SDGR or AMRN?

Which has higher earnings and valuation, SDGR or AMRN?

Does the media prefer SDGR or AMRN?

Is SDGR or AMRN more profitable?

Which has more risk and volatility, SDGR or AMRN?

Summary

How does Amarin compare to Avalyn Pharma?

Does the media prefer AMRN or AVLN?

Do institutionals and insiders hold more shares of AMRN or AVLN?

Is AMRN or AVLN more profitable?

Which has higher valuation & earnings, AMRN or AVLN?

Do analysts prefer AMRN or AVLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRN vs. The Competition

Amarin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools